LawPlayer
My bookmarks
Source

Commission Implementing Regulation (EU) 2022/1255 of 19 July 2022 designating antimicrobials or groups of antimicrobials reserved for treatment of certain infections in humans, in accordance with Regulation (EU) 2019/6 of the European Parliament and of the Council (Text with EEA relevance)

Commission Implementing Regulation (EU) 2022/1255 of 19 July 2022 designating antimicrobials or groups of antimicrobials reserved for treatment of certain infections in humans, in accordance with Regulation (EU) 2019/6 of the European Parliament and of the Council (Text with EEA relevance)

Implementing Regulation (EU) 2022/1255 · Regulation · 3 articles

Data as of 2026-07-04 · Compiled from an official source version. Later amendments or repeals may not be reflected; the official text prevails. · Read the official text ↗

Antimicrobials or groups of antimicrobials designated as reserved for treatment of certain infections in humans

Article 1

Open ↗

1.   The antimicrobials and groups of antimicrobials listed in the Annex shall not be used in veterinary medicinal products or medicated feed. 2.   The use in animals of medicinal products for human use that contain any of the antimicrobials or groups of antimicrobials listed in the Annex is prohibited.

Entry into force and application

Article 2

Open ↗

This Regulation shall enter into force on the twentieth day following that of its publication in the Official Journal of the European Union . It shall apply from 9 February 2023.

Supplementary provisions

Antimicrobials or groups of antimicrobials reserved for treatment of certain infections in humans

ANNEXSupplementary provisions

Open ↗

ANNEX Antimicrobials or groups of antimicrobials reserved for treatment of certain infections in humans (1)    Antibiotics (a) Carboxypenicillins (b) Ureidopenicillins (c) Ceftobiprole (d) Ceftaroline (e) Combinations of cephalosporins with beta-lactamase inhibitors (f) Siderophore cephalosporins (g) Carbapenems (h) Penems (i) Monobactams (j) Phosphonic acid derivates (k) Glycopeptides (l) Lipopeptides (m) Oxazolidinones (n) Fidaxomicin (o) Plazomicin (p) Glycylcyclines (q) Eravacycline (r) Omadacycline (2)    Antivirals (a) Amantadine (b) Baloxavir marboxil (c) Celgosivir (d) Favipiravir (e) Galidesivir (f) Lactimidomycin (g) Laninamivir (h) Methisazone/metisazone (i) Molnupiravir (j) Nitazoxanide (k) Oseltamivir (l) Peramivir (m) Ribavirin (n) Rimantadine (o) Tizoxanide (p) Triazavirin (q) Umifenovir (r) Zanamivir (3)    Antiprotozoals (a) Nitazoxanide

Other acts of the same type
Commission Regulation (EU) 2021/663 of 22 April 2021 amending Annex III to Regulation (EC) No 396/2005 of the European Parliament and of the Council as regards maximum residue levels for chlordecone in or on certain products (Text with EEA relevance)Commission Implementing Regulation (EU) 2021/664 of 22 April 2021 on a regulatory framework for the U-space (Text with EEA relevance)Commission Implementing Regulation (EU) 2021/665 of 22 April 2021 amending Implementing Regulation (EU) 2017/373 as regards requirements for providers of air traffic management/air navigation services and other air traffic management network functions in the U-space airspace designated in controlled airspace (Text with EEA relevance)Commission Implementing Regulation (EU) 2021/666 of 22 April 2021 amending Regulation (EU) No 923/2012 as regards requirements for manned aviation operating in U-space airspace (Text with EEA relevance)Commission Implementing Regulation (EU) 2021/685 of 22 April 2021 correcting the Polish language version of Regulation (EU) No 1321/2014 on the continuing airworthiness of aircraft and aeronautical products, parts and appliances, and on the approval of organisations and personnel involved in these tasks (Text with EEA relevance)Commission Delegated Regulation (EU) 2021/1340 of 22 April 2021 supplementing Directive 2014/59/EU of the European Parliament and of the Council with regard to regulatory technical standards determining the content of the contractual terms on recognition of resolution stay powers (Text with EEA relevance)Commission Implementing Regulation (EU) 2021/655 of 21 April 2021 amending Council Regulation (EC) No 1210/2003 concerning certain specific restrictions on economic and financial relations with IraqCommission Implementing Regulation (EU) 2021/656 of 21 April 2021 entering a name in the register of Traditional Specialities Guaranteed (‘Slovenska potica’ (TSG))Commission Implementing Regulation (EU) 2021/657 of 21 April 2021 entering a name in the register of protected designations of origin and protected geographical indications (‘Caşcaval de Săveni’ (PGI))Commission Implementing Regulation (EU) 2021/658 of 21 April 2021 concerning the authorisation of essential oil from Origanum vulgare L. subsp. hirtum (Link) letsw. Var. Vulkan (DOS 00001) as a feed additive for all animal species (Text with EEA relevance)Commission Delegated Regulation (EU) 2021/1096 of 21 April 2021 amending Regulation (EU) 2019/787 of the European Parliament and of the Council as regards labelling provisions for blendsCommission Delegated Regulation (EU) 2021/1253 of 21 April 2021 amending Delegated Regulation (EU) 2017/565 as regards the integration of sustainability factors, risks and preferences into certain organisational requirements and operating conditions for investment firms (Text with EEA relevance)

Source: EUR-Lex (Publications Office of the EU), © European Union, reuse permitted under Commission Decision 2011/833/EU.

Contents

What to look at next